WHIPPANY, NJ–(BUSINESS WIRE)–Bayer today announced that Astepro® Allergy (azelastine hydrochloride 0.15%) is now available over-the-counter at retail stores nationwide. It is the first and only over-the-counter steroid-free antihistamine nasal spray for indoor and outdoor allergies, and the only over-the-counter anti-allergy spray that starts working in 30 minutes, while others take hours.
Astepro® Allergy provides temporary relief of nasal congestion, runny nose, sneezing and itchy nose due to hay fever or other upper respiratory allergies for adults and children 6 years and older. The treatment, which received FDA approval last year, will provide more than 50 million Americans with allergies with access toI ready anytime, fast allergy relief.
“At Bayer, our mission is to provide products that enable people to live healthier lives every day, and that means providing proven relief from their seasonal and indoor allergy symptoms whenever they arise,” said said Catherine Vennat, Vice President/General Manager, Upper Respiratory, Bayer Consumer Health US “Allergy sufferers now have access to the fastest nasal allergy medication available over-the-counter in 24 hours with Steroid-Free Astepro® Allergy. – a breakthrough in the category. Thanks to the speed of our product, allergy sufferers can enjoy the moment without worrying about when they will feel relief.
This prescription over-the-counter formulation includes a number of benefits, one of which is flexible once or twice daily dosing that provides relief for up to 24 hours. Other allergy nasal sprays require three to four days of continuous use for full effectiveness. Astepro® Allergy is available nationwide at mass retail outlets. For more information, please visit https://www.asteproallergy.com/ or follow us on Instagram and Twitter.
Bayer is a global company with core competencies in the areas of life sciences healthcare and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its profitability and create value through innovation and growth. Bayer is committed to the principles of sustainable development and the Bayer brand is synonymous with trust, reliability and quality around the world. During the 2019 financial year, the Group employed around 104,000 people and achieved a turnover of 43.5 billion euros. Capital expenditure amounted to 2.9 billion euros, R&D expenditure to 5.3 billion euros. For more information, visit www.bayer.com.
This press release may contain forward-looking statements based on current assumptions and forecasts made by Bayer’s management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on Bayer’s website at www.bayer.com. The company assumes no responsibility for updating these forward-looking statements or adapting them to future events or developments.
I American College of Allergy, Asthma and Immunology. Done quick. 2014. https://acaai.org/news/facts-statistics/allergy